

CRISPR Market Growth at 16.8% CAGR, Expected to Reach US\$15.25B by 2033, North America Holds 42%

CRISPR Market to Reach US\$15.25B by 2033 at 16.8% CAGR, Led by Thermo Fisher, Merck, Agilent; North America Holds 42%

LEANDER, TX, UNITED STATES, December 17, 2025 / EINPresswire.com/ -- According to DataM Intelligence, the Global [CRISPR Market](#) reached US\$ 3.93 billion in 2024 and is projected to grow substantially to US\$ 15.25 billion by 2033, expanding at a strong CAGR of 16.8% during the forecast period 2025–2033. Market growth is driven by the rising adoption of CRISPR gene-editing technology across medicine, agriculture, and biotechnology, owing to its high precision, efficiency, and cost-effectiveness. Increasing investments in genomic research, growing prevalence of genetic disorders, and accelerating demand for advanced gene therapies and personalized medicine are further fueling market expansion.

“

The CRISPR market is experiencing significant growth as gene-editing technology enables precise DNA modifications, driving innovation and adoption across medicine, agriculture, and biotechnology”

DataM Intelligence



CRISPR technology, enabled by enzymes such as Cas9, allows precise modification of DNA, making it a transformative tool for gene therapy, cancer research, crop improvement, and disease modeling. CRISPR kits and consumables are witnessing strong demand as they simplify experimental workflows and enhance accessibility for academic, research, and clinical laboratories. In addition, CRISPR libraries, consisting of large collections of guide RNAs, are playing a critical role in large-scale gene function studies and drug discovery. Continuous innovation, expanding clinical applications, and supportive

regulatory frameworks are expected to sustain robust growth in the global CRISPR market.

Download your exclusive sample report today: (corporate email gets priority access):

<https://www.datamintelligence.com/download-sample/crispr-market>

Key Highlights from the Report:

The global CRISPR market is growing rapidly due to increasing adoption of gene-editing technologies across healthcare, biotechnology, agriculture, and research applications.

Market growth is driven by strong research and development investments and expanding use of CRISPR in drug discovery, genetic disease treatment, personalized medicine, and crop improvement.

Kits, reagents, and consumables account for a major share of the market, supported by recurring demand from academic and commercial research laboratories.

Academic and research institutes, pharmaceutical and biotechnology companies, and agricultural organizations are key end users of CRISPR technologies.

North America leads the market due to advanced research infrastructure, while Asia-Pacific is emerging as the fastest-growing region with increasing biotechnology investments.

Key Segments

By Product Type

CRISPR kits & consumables dominate the market as they are essential for routine gene-editing workflows across research laboratories, pharmaceutical companies, and academic institutions. The segment benefits from recurring demand for reagents, enzymes, guide RNAs, and delivery systems, making it a primary revenue generator. Continuous improvements in accuracy, ease of use, and compatibility with multiple CRISPR systems further support growth.

CRISPR libraries are witnessing strong expansion due to their increasing use in large-scale functional genomics, target validation, and high-throughput screening applications, particularly in drug discovery and cancer research.

Other product types, including CRISPR design software, delivery vectors, and custom gene-editing solutions, contribute steadily as end users seek integrated and specialized tools for complex research needs.

By Application

Drug discovery & development holds the largest share as CRISPR technology accelerates target identification, disease modeling, and preclinical validation, significantly reducing development timelines and costs. Pharmaceutical and biotechnology companies increasingly rely on CRISPR-based screening and gene-editing platforms to advance precision therapeutics.

Agriculture is a rapidly growing application area, driven by rising demand for genetically improved crops with enhanced yield, disease resistance, and climate resilience. CRISPR's

precision and regulatory advantages over traditional genetic modification support its adoption in crop and livestock improvement.

Buy Now & Unlock 360° Market Intelligence: <https://www.datamintelligence.com/buy-now-page?report=crispr-market>

Key Players

Thermo Fisher Scientific, Inc. | Merck KGaA | Agilent Technologies, Inc. | GenScript | Creative Biogene | Bio-Rad Laboratories, Inc. | Takara Bio Inc. | QIAGEN | Eurofins Genomics | Synthego

Key Highlights

Thermo Fisher Scientific, Inc. - Holds a share of 18.7%: Leads the CRISPR tools market with a broad portfolio of genome editing reagents, instruments, and integrated workflows for research and therapeutic development.

Merck KGaA - Holds a share of 16.2%: Provides licensed CRISPR technologies, high-quality reagents, and genome editing platforms supporting academic and biopharma research.

Agilent Technologies, Inc. - Holds a share of 10.4%: Offers analytical instruments and reagents that support CRISPR-based research, validation, and quality control.

GenScript - Holds a share of 9.1%: Specializes in custom gene synthesis, CRISPR libraries, and genome editing services for research and industrial biotechnology.

Creative Biogene - Holds a share of 5.6%: Provides contract research services and customized CRISPR solutions for gene editing and functional genomics studies.

Bio-Rad Laboratories, Inc. - Holds a share of 8.9%: Supplies PCR, digital PCR, and gene expression tools essential for CRISPR validation and genomic analysis.

Takara Bio Inc. - Holds a share of 7.8%: Develops CRISPR/Cas systems, cloning kits, and reagents optimized for high-efficiency genome editing.

QIAGEN - Holds a share of 6.7%: Offers sample preparation, gene expression, and bioinformatics solutions supporting CRISPR research workflows.

Eurofins Genomics - Holds a share of 8.1%: Provides sequencing, synthesis, and validation services essential for CRISPR experiments and quality assurance.

Synthego - Holds a share of 8.5%: Focuses on synthetic guide RNAs, engineered CRISPR tools, and cell engineering services for research and therapeutic applications.

Regional Insights

- North America – 42% driven by "strong presence of leading biotech and life sciences companies, high R&D expenditure in genetic engineering, robust funding for CRISPR research, and widespread adoption in therapeutics, agriculture, and diagnostics."
- Europe – 28% supported by "growing investments in genomic research, supportive regulatory frameworks for gene editing in research, increasing collaborations between academia and industry, and rising applications in precision medicine and plant biotechnology."
- Asia-Pacific – 20% fueled by "rapid expansion of biotechnology sectors in China, Japan, and India, increasing government funding for life science innovation, and rising adoption of CRISPR technologies in research and commercial applications."
- Latin America – 6% driven by "emerging biotech research infrastructure, growing interest in agricultural and therapeutic gene editing, and increasing academic and startup activities in CRISPR applications."
- Middle East & Africa – 4% supported by "gradual development of life sciences ecosystems, rising investments in healthcare and biotechnology research, and growing awareness of CRISPR's potential for disease treatment and agricultural improvements."

Get Customization in the report as per your requirements:

<https://www.datamintelligence.com/customize/crispr-market>

Key Developments

November 2025: Clinical trial outcomes from a CRISPR-based therapy demonstrated strong potential in treating common chronic conditions by permanently switching off disease-causing genes, signaling expansion beyond rare genetic disorders.

October 2025: A global pharmaceutical company entered a strategic collaboration to secure long-term access to advanced CRISPR gene-editing platforms, reinforcing industry confidence in CRISPR as a core therapeutic technology.

August 2025: Market activity reflected growing adoption of CRISPR across healthcare, agriculture, and industrial biotechnology, supported by rising investment in precision genomics and functional gene-editing applications.

June 2025: A major pharmaceutical acquisition of a CRISPR-focused biotechnology company was announced, aimed at strengthening gene-editing pipelines in cardiovascular, metabolic, and inherited disease segments.

May 2025: A next-generation CRISPR editing tool designed to enhance insertion accuracy and editing efficiency was introduced, highlighting continued innovation in genome-engineering

technologies.

January 2025: Expansion of CRISPR-based diagnostics and research infrastructure gained momentum, with new facilities dedicated to rare disease detection, infectious disease monitoring, and antimicrobial resistance research.

Frequently Asked Questions (FAQs):

How big is the global CRISPR market in terms of growth forecast?

The global CRISPR market was valued at around US\$ 3.93 billion in 2024 and is expected to grow strongly over the forecast period.

What is the projected CAGR for the CRISPR market?

The market is projected to grow at a CAGR of 16.8% during 2025–2033.

What is the expected market size by 2033?

By 2033, the CRISPR market is expected to reach approximately US\$ 15.25 billion.

Which product or offering segment leads the CRISPR market?

CRISPR kits and consumables lead the market due to their widespread use in research laboratories and biotechnology companies.

Which application segment dominates the CRISPR market?

Biomedical research and drug discovery dominate the market, driven by increasing use of CRISPR in gene editing, functional genomics, and therapeutic development.

Conclusion:

The global CRISPR market is experiencing strong growth, driven by expanding applications in gene therapy, precision medicine, agriculture, and biotechnology research. Gene-editing technologies are increasingly used to develop treatments for genetic disorders, enhance crop traits, and accelerate biomedical research, reflecting broad commercial and scientific interest. Advances in delivery systems, editing accuracy, and innovative platforms such as base and prime editing are further strengthening adoption across multiple sectors.

While challenges such as regulatory and ethical considerations, delivery complexities, and safety concerns remain, ongoing innovation, rising research investments, and expanding use cases indicate that CRISPR technologies are poised to become foundational tools in healthcare and agriculture, enabling improved outcomes and new capabilities worldwide.

Related Reports:

1. [CRISPR-Based Diagnostics Market](#)
2. [Prime Editing and CRISPR Market](#)

Sai Kiran

DataM Intelligence 4market Research LLP

+1 877-441-4866

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/876113581>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.